<DOC>
	<DOC>NCT01390012</DOC>
	<brief_summary>The purpose of this study is to assess bioequivalence for dexamethasone administered orally versus intravenously in patients admitted to hospital for pneumonia.</brief_summary>
	<brief_title>Oral Versus Intravenous Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Aged 18 years and older Presenting to the emergency room with suspected pneumonia (to be confirmed within 24 hours from admission) Pneumonia is defined as a new or progressive infiltrate on a chest Xray plus at least two of the following criteria: cough, sputum production, temperature &gt;38°C or &lt;35°C, auscultatory findings consistent with pneumonia, leucocytosis or leucopenia (&gt;10 g/l, &lt;4 g/l or &gt;10% rods in leucocyte differentiation), Creactive protein &gt;3 times the upper normal limit Corticosteroid naive at time of presentation Patients needing corticosteroid treatment above study medication Failure to obtain written consent to participate Patients using medication drugs that interact with dexamethasone (i.e. phenytoin, barbiturates, rifampicin, erythromycin, clarithromycin, aprepitant, colchicine, everolimus, itraconazole, ketoconazole, pazopanib, tipranavir, and vinorelbine) Moribund patients (defined as expected to die within 24 hours) Patients with proven or suspected allergy to dexamethasone Patients not capable of taking tablets orally</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>